Memorial Sloan Kettering Cancer Center, New York, NY

  • Clinical trial
    2012 – 2014

    FCF funded the first clinical trial of drugs aimed specifically at fibrolamellar liver cancer.  This trial was coordinated by Dr. Ghassan Abou-Alfa at Memorial Sloan Kettering Cancer Center (MSKCC). The trial was also conducted at other consortium members, including the University of California San Francisco, Johns Hopkins, and Dana Farber. Two major pharmaceutical companies donated the drugs.  

    MSKCC is sequencing the exome of the fibrolamellar genome.

    MSKCC is the coordinator of the Fibrolamellar Consortium.

Leave a Comment